Stempa BO

Language: Spanish
References: 35
Page: 84-90
PDF size: 94.78 Kb.

ABSTRACT

The entero – insular axis is a system in which gut peptides called incretins, enhance insulin synthesis and secretion by the beta cells after binding to specific receptors. Type 1 glucagon like peptide (GLP-1) has been the best characterized incretin and its deficiency in type 2 diabetes patients was demonstrated in several studies. Exenatide was the first GLP-1 mimetic used in patients with type 2 diabetes. There are two additional drugs, liraglutide and albiglutide, which are GLP-1 analogues and share many of the native GLP-1 effects. Their efficacy, in terms of glycohemoglobin, has proved to be similar to that of insulin but with the advantage of minimizing the risk of hipoglycemia. An antiapoptotic effect on beta cells has been proposed in animal models as well as in human cells cultured in vitro, which needs further investigation.

REFERENCES

1. Salehi M, D’alessio DA. New therapies for type 2 diabetes base don glucagon - like peptide-1. Cleveland Clinic Journal of Medicine 2006; 73: 382-89.

2. Kieffer TJ, Habener JF. The glucagon–like peptides. Endocr Rev 1999; 20: 876-913.

3. Hoogwerf BJ. Exenatide and pramlintide: New glucose lowering agents for treating diabetes mellitus. Cleveland Clinic Journal of Medicine 2006; 73: 477-84.

4. Nauck MA, Homeberger E, Siegel EG et al. Incretins effects on increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492-98.

5. Drucker DJ, Nauck MA. The incretin system: glucagon – like peptide-1 receptor agonists and dipeptidyl peptidase – 4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1969-705.

6. Van Gaal LF, Gutkin SW, Nauck MA. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon – like peptide-1 receptor agonists or insulin for patients with inadequate glycemic control? Eur J Endocrinol 2008; 158: 773-84.

7. Starich GH, Bar RS, Mazzaferri EL. GIP increases insulin receptor affinity and celular sensitivity in adipocytes. Am J Physiology 1985; 249: E603-E607.

8. Kacsoh B. The endocrine pancreas. En: Kacsoh B. Endocrine Physiology; McGraw-Hill, 2000: 209.

9. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon – like peptide-1 (7-36) amide and glucose dependent insulinotrophic polypeptide secretion in response to nutrient ingestion in mess: acute post-prandial and 24-h secretion patterns. J Endocrinol 1993; 138: 159-66.

10. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon – like peptide-1 by human plasma in vitro yields an N – terminal truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952-57.

11. Dungan K, Buse JB. Glucagon – like peptide-1 Based therapies for Type 2 Diabetes: A focus on Exenatide. Clinical Diabetes 2005; 23: 56-62.

12. Scrocchi LA, Brown TJ, Maclusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon – like peptide-1 receptor gene. Nature Med 1996; 2: 1254-58.

13. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-65.

14. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycemia by exogenous glucagon – like peptide-1 (7-36 amide) in type 2 (non – insulin dependent) diabetic patients. Diabetología 1993; 36: 741-44.

15. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon – like peptide-1 on glycaemic control, insulin sensitivity, and beta cell function in type-2 diabetes: a parallel – group study. Lancet 2002; 359: 824-30.

16. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years’ therapy of type – II diabetes: a progressive disease. Diabetes 1995; 44: 1249-58.

17. Hinnen D, Nielsen LL, Waninger A, Kushner P. Incretin mimetics and DPP-IV inhibitors: New paradigms for the treatment of type – 2 diabetes. JABFM 2006; 19: 612-20.

18. Toft – Nielsen MB, Madsbad S, Holst JJ. Determinants of the effectiveness of glucagon – like peptide-1 in type-2 diabetes. J Clin Endocrinol Metab 2001; 86: 3853-60.

19. Rachman J, Gribble FM, Borrow BA, Levy JC, Buchanan KD, Turner RC. Normalization of insulin responses to glucose by overnight infusion of glucagon – like peptide-1 (7-36) amide in patients with NIDDM. Diabetes 1996; 45: 1524-1530.

20. VilsbØll T, Zdravkovic M, Le – Thi T et al. Liraglutide significantly improves glycemic control and lowers body weight without risk of either major or minor hypoglycemic episodes in patients with type-2 diabetes. Diabetes 2006; 55 (Suppl 1): 27 – 28 (abstr 115 – OR).

21. Matthews JE, Stewart MW, De Boever EH, Dobbins RL, Hodge RJ, Walker SE et al. Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a long acting Glucagon-like peptide – 1 mimetic in patients with type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 4810-4817.

22. Egan JM, Cloquet AR, Elahi D. The insulinotrophic effect of acute exendine-4 administrated tu humans: comparison of non diabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002; 87: 1282-1290.

23. Egan JM, Meneilly GS, Elahi D. Effects of 1-mo bolus subcutaneous administration of exendine-4 in type 2 diabetes. Am J Physiol Endocrinol Metab 2003; 284: E1072 – E1079.

24. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendine-4) on glycemic control over 30 weeks in sulfonilurea – treated patients with type-2 diabetes. Diabetes Care 2004; 27: 2628-35.

25. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type-2 diabetes. Ann Intern Med 2005; 143: 559-69.

26. Edwards CMB, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ et al. Exendine-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281: E155–E161.

27. Abraham EJ, Leech CA, Lin JC, Zulewski H, Habener JF. Insulinotropic hormone glucagon – like peptide-1 differentiation of human pancreatic islet – derived progenitor cells into insulin-producing cells. Endocrinology 2002; 143: 3152-61.

28. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendine-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type-2 diabetes. Diabetes Care 2005; 28: 1092-1100.

29. Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendine-4) on glycemic control over 30 weeks in patients with type-2 diabetes treated with metformin and a sulfonilurea. Diabetes Care 2005; 28: 1083-1091.

30. www.amylin.com

31. Health Agencies Update. Exenatide risk. JAMA 1008; 300: 1403.

32. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement of The American Diabetes Association and The European Association for the Study of Diabetes. Diabetes Care 2008; 31: 1-11.

33. Ahmad SR, Swann J, Bloomgren G, Braun D, Kolterman O. Exenatide and rare adverse events. New Engl J Med 2008; 358: 1969-1972.

34. Kim D, Mac Connell L, Zhuang D et al. Safety and efficacy of a once – weekly, long – acting release formulation of Exenatide over 15 weeks in patients with type-2 diabetes. Diabetes 2006; 55 (Suppl 1): 116 (Abstr 487 – P).

35. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomized, open – label, non – inferiority study. Lancet 2008; 372: 1240-50.